Another study by Aldoss et al. [69] revealed a response of 42% among R/R AML patients with FLT3 mutations, better in those who were naïve for FLT3-based TKIs (37% for patients with prior exposure vs. 50% in naïve). Here, FLT3 is linked to acute myeloid leukemia.